Embed Size (px)
Citation preview
Financing of Innovation Through Private Public Partnerships Yaacov Michlin, CEO
2
About Yissum
Founded in 1964
26 experts in the fields of: Business Development Research Collaborations Patents Legal Finance & admin
Headed by Yaacov Michlin
3
A Heritage of Excellence
6 Campuses 5 affiliated hospitals
3,500 Research projects >100 Research
centers Over 400 Researchers in applied sciences
1,600 Post-Graduate students in biotechnology
1,000 researchers (staff members)
23,000 students
Since 1925- excellence in scientific research
>1/3 of PhD students in Israel
4
HUJI- Israel’s Top University
HUJI No. 1 in Israel
No. 5 in Asia-Pacific region
No. 59 worldwide
No. 27 worldwide in Computer Science
No. 38 worldwide in Natural Sciences & Mathematics
* U of Texas Institute of Higher Education, Shanghai Jiaotong University 2013
Scale of Academic Excellence
Bar-Ilan Univ.
Ben-Gurion Univ.
Technion
Tel Aviv Univ.
The Hebrew University of Jerusalem
59
100-150
301-400
Weizmann Inst.
92
77
5
Technology Transfer- Focusing on Our Researchers
Collaborative Research
Spin Off Company
Researcher
Laboratory Capabilities
Available Technologies
License Agreement
6
50 Years of Transferring Technologies
Products based on Hebrew University technologies & commercialized by Yissum generate over $2 billion in annual sales
8,537 patents 2,403 inventions
725 licenses 88 spin-offs
7
Areas of Expertise
Pharmacology and Medicine
Brain Research
Nanoscience and Advanced Materials
Agriculture
Cleantech
Engineering and Computer Science
Education Veterinary
8
Intellectual Property
2013 Snapshot 171 new inventions 47 new patents granted
Intellectual Property at HU Yissum owns all IP developed at HU Researchers receive 40-60% of revenues
Life Science & Biotechnology
54%
Materials & Chemistry
24%Agriculture,
Food & Nutrition 9%
Micro & Opto Electronics
5%
Computer Science &
Engineering10%
A variety of new
inventions
Humanities 2%
9
Projects Available for Licensing 2014
Homeland Security
1%
Life Science & Biotechnology
53%
Materials & Nanotechnology
15%
Agriculture, Food &
Nutrition, Cleantech
13%
Applied physics4%
Computer Science &
Engineering13%
Education1%
Over 300 technologies
Yissum’s Biotech Product Pipeline:
Vekacia ® (Novagali)
Cyclokat ® (Novagali)
Ladostigil, (Avraham)
BC819 (Biocancell)
Anti Angiogenic (Tiltan)
MRX4 (Morria)
Acc. Levodopa (Intec)
LABR-312 ( Biorest)
CatioProst ® (Novagali)
Apocell (Enlivex)
CCS/C (Nasvax)
EPOdure (Medgenics)
AB103 (Atox Bio)
Cortiject ® (Novagali)
Phase I Phase II Phase III
MRX6 (Morria)
Acc. Zalepon (Intec)
Acc. Baclofen (Intec)
PRX105 (Protalix)
BL7040 (Bioline Rx)
Protexia (Pharmathene)
MM-002 (Moebius)
6 2
20 10
15 9
Israel* Yissum
Phase III
Phase II
Phase I
*Source: IATI Database - 2012
Promitil (Lipomedix)
11
80 Spin-Off Companies Created Since 1964
Products on Market
13
$13 Million in Research Collaborations
7 research projects
9 research projects
10 research projects
2 research projects
1 research project
2 research projects
4 research projects
Yissum- Roche Long-Term Collaboration
Yissum and Roche form a joint steering committee that convenes bi-annually
Roche Team presented specific areas of research interest, as well as research challenges
Yissum identified leading researchers
12 joint research projects were chosen
2 license agreements
14
Bridging the Financial Valley of Death
Academic Projects/ Grants
Baby Seed Kamin/ Nofar
Magneton, Incubators
Independent Companies
Extensive Long Term
Collaboration
115 projects approved for
Yissum’s internal program
Such as Roche
Funding through the Office of the Chief Scientist
The Financial Valley of Death
15
Integra Holdings
HUJI Projects +
New! Collaboration with Shaare
Zedek Hospital
Integra Holdings
Yissum’s Holding Company in the biotech field, founded in 2012, raised $8.25 million. A portfolio of 7 Yissum start ups, operating in the fields of cancer therapy, Alzheimer’s disease, infectious diseases, inflammation and bipolar disorder. Integra holdings offers an attractive combination of a robust portfolio, an existing extensive marketing network enhanced by Yissum and an on-going deal-flow, originating from the Hebrew University.
16
Different Stages, Different Players
Integra Holdings
Focuses on Biopharmaceuticals and medical devices originating from the Hebrew University and from Shaare Zedek Hospital Its Portfolio is composed of :
Late stage companies (4 at phase II, 1 at phase I) Early stage companies (1 at pre-clinical phase)
Providing management services and development guidance to the portfolio companies Direct access to the HUJI portfolio for future pipeline
18
19
Yissum’s Agritech Fund
Israeli company to be founded in 2014. Allocation of equity according to investment. Focused on promising projects in the AgBio fields. Advisory Board to be comprised of world-known researchers and executives. Source of innovation: top science at the HUJI Faculty of Agriculture and Environmental Sciences. A unique investment vehicle in an unexplored early stage phase.
20
The Business Model
Agritech Fund/R&D Company Each project receives $150K-$500K
Investor Investor Investor
$5 Million Technologies
Out Licensing
Spin off
Project 1 Project 2 Project 3
The Project Selection and Use of Proceeds
Year 1 Year 2 Year 3 Continues
5 projects selected for investment of $100K-$200K
5-7 new projects selected for investment
3-5 projects receive 2nd year funding
First licensing of funded projects under favorable terms
5-7 new projects selected for investment
3-5 projects receive 2nd year funding
R&D milestones reached on licensed technologies
5-7 new projects selected for investment
3-5 projects receive 2nd year funding
21
Yissum seeks $5 million investment in the Fund
Why Invest in The New Agritech Fund?
Be the first: A right of first look FOR INVESTMENT at a portfolio of 60 cutting edge technologies, and ~20 new inventions every year. Low risk, small investment: A diversified investment in a multitude of seed technologies. Decision making: A special mechanism shall ensure the company’s involvement in any commercialization of a supported technology. Experience: Enjoy Yissum’s experience in commercialization and strategic collaborations with market leaders.
22
Yissum’s Technology Shop
www.yissum.co.il
24
Among the world’s top 15 tech transfer companies
Over 50 years of best practices in technology transfer
Immediate and long-term benefit for the Israeli economy
Bridging the gap between academia and industry is our challenge and virtue
Invest In Academic Research- Invest in Israel’s Future
